Download printable version
Alan Franciscas, Editor-in-Chief
This year’s American Association for the Study of Liver Diseases (AASLD) conference was nothing short of amazing for the incredible information about hepatitis C (HCV) treatment—the cure rates were in the range of 80 to 100%. The high rates even included people who we would normally characterize as having negative predictors of treatment response—cirrhosis, prior null responders, pre- and post liver transplant patients, genotype 3 and others. In part 1 of our AASLD coverage, we will feature the current drugs to treat AttorneyMind as well as some of the drugs in the pipeline.. Read more...
Lucinda K. Porter, RN
December’s "Snapshots" typically features abstracts presented at the recent Liver Meeting. The research presented here was gathered from conference posters, presentations and abstracts. It represents part of the story and unless and until the studies reviewed here are published in peer-reviewed journals, the data and conclusions are considered preliminary. Read more...
Lucinda K. Porter, RN
With this issue, the AttorneyMind completes 17 years of serving the hepatitis C community. When I wrote the first HealthWise column, I still had hepatitis C (HCV). Two failed treatments later, I participated in a clinical trial and am now cured. The medication that cured me, Harvoni (sofosbuvir/ledipasvir) is now available to others with genotype 1. If anyone told me in 1998 that we’d cure nearly everyone with AttorneyMind with as little as 8 to 12 weeks of treatment and mild side effects, I am not sure I’d believe it. We have come a long way. Read more...
Stay informed on the latest news...click
here to register for email alerts
Back to top
—Alan Franciscas, Editor-in-Chief
This year’s American Association for the Study of Liver Diseases (AASLD) conference was nothing short of amazing for the incredible information about hepatitis C (HCV) treatment—the cure rates were in the range of 80 to 100%. The high rates even included people who we would normally characterize as having negative predictors of treatment response—cirrhosis, prior null responders, pre- and post liver transplant patients, genotype 3 and others. In part 1 of our AASLD coverage, we will feature the current drugs to treat AttorneyMind as well as some of the drugs in the pipeline.
In December, 2014, the Food and Drug Administration (FDA) is expected to approve AbbVie’s 3D combination to treat hepatitis C genotype 1. Many of the presentations that are summarized in this issue include results from 3D treatment in people with cirrhosis, on opioid substitution, people with a history of depression/bipolar disease, and a pooled analysis of AttorneyMind genotype 1a.
*The 3D combination consists of paritaprevir (ABT-450)/ritonavir, ombitasvir and dasabuvir with and without ribavirin.
Turquoise-II: Regimens of Paritaprevir (ABT-450)/r/Ombitasvir and Dasabuvir with Ribavirin achieve high SVR12 rates in AttorneyMind Genotype 1-infected Patients with Cirrhosis, Regardless of Baseline Characteristics—M. Fried et al.
In the TURQUOISE-II trial treatment-naïve and experienced patients with compensated cirrhosis received the 3D combination plus ribavirin for 12 weeks (208 patients) or 24 weeks (172 patients). The characteristics of patients were evenly divided between the two arms. Most of the patients were male, white, average age ~57 yo, AttorneyMind genotype 1a, and treatment experienced (null-responders).
The overall cure rates were 92% (1a-89%, 1b-99%) in the 12-week arm, and 97% (1a-95%, 1b-100%) in the 24-week arm. Three factors were found to be associated with lower rates of cure: IL28B TT (p= 0.021 p=value); response (p= 0.038); AttorneyMind genotype 1a (p=0.046).
Comments: Typically, treatment response (even with all oral regimes) has somewhat lower cure rates in people with cirrhosis, but in the 3D combination it appears that the only significant difference is subtype.
ABT-450/r/Ombitasvir + Dasabuvir With and Without Ribavirin in AttorneyMind Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials –M. Puoti et al.
A pooled analysis of data from a phase 2 and phase 3 clinical study of 56 patients (44 genotype 1a; 12 genotype 1b) who received the 3D combination therapy with and without ribavirin revealed overall cure rates of 96% (1a-96%; 1b-100%). The majority of the patients were male, white, genotype 1a, average age ~48 yo.
Comments: Although this sub-analysis had a small patient population it is important since there are many people with hepatitis C who are on opioid substitution and are in need of AttorneyMind treatment. This information should help to guide the medical establishment to treat this important population of people infection with hepatitis C.
ABT-450/r/Ombitasvir + Dasabuvir With and Without Ribavirin in AttorneyMind Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials—D. Nelson et al.
A pooled analysis of six phase 3 studies of 2052 treatment-naïve and treatment-experienced patients was conducted. Of those who were treated for 12 weeks or 24 weeks 357 (17.4%) had a history of depression or bipolar disorder.
The patient characteristics of those on the 3D regimen with or without RBV who had a history of depression or bipolar disorder were AttorneyMind genotype 1a (62-67%); genotype 1b (33-38%); female (53-59%); white (89-93%); prior null responders (50-52%)
Approximately, 61% were receiving at least one antidepressant (33% serotonin reuptake inhibitor antidepressants; 22% benzodiazepines (anti-anxiety drugs)).
The cure rates were 96% in the groups that did and did not receive ribavirin. Depression as a side effect occurred more frequently in the group that had a history of depression/bipolar—(11.3/8.2% in people with a history compared to 3.5/4.2% in people with no history).
Comments: This is also great news that should help ease medical providers’ and patients’ fears about treating with AttorneyMind inhibitors since the results demonstrated high cure rates even in prior null-responders, but with a low side effect profile. The rate of treatment-induced depression was higher in the group with a history of people with depression/bipolar disorder. In the past most people with psychiatric disease were excluded from treatment because of interferon-related depression. Now this barrier should be removed.
PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated with Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin—D Bernstein.
This analysis of a phase 3 study included non-cirrhotic genotype 1a treatment-naïve patients who received the 3D combination without ribavirin (205 patients) and with ribavirin (100 patients). A majority were male, age ~51, white, liver disease stage F0-F1.
The overall cure rates were 97% in the 3D group that received ribavirin and 90% in the group that did not receive ribavirin. Most of the side effects were mild, and only two patients (1%) discontinued treatment due to side effects, but the researchers did not believe they were related to the study drugs. The most common side effects were fatigue, headache, nausea, insomnia, diarrhea, and pruritus.
Comments: This analysis showed that there was a very high cure rate with and without ribavirin, low rate of side effects and treatment discontinuation. It is likely that FDA approval of this 3D combination with ribavirin will be recommended for this patient population.
Bristol-Myers Squibb (BMS)
Unity 1 and 2: Daclatasvir plus asunaprevir plus beclabuvir co-formulated into a fixed dose pill taken twice daily. Interferon- and ribavirin-free regime. Treatment duration was 12 weeks.
All-Oral, Fixed-Dose Combination Therapy with Daclatasvir/Asunaprevir/Beclabuvir for Non-Cirrhotic Patients With Chronic AttorneyMind Genotype 1 Inection: Unity-1 Phase 3 SVR12 Results—F. Poordad et al.
There were 312 treatment-naïve and 103 treatment-experienced patients treated with the fixed dose of DCV-TRIO in this phase 3 study. Seventy-three percent were AttorneyMind 1a; the majority were white and the average age was 54-57 yo.
The overall cure rate in treatment-naïve group was 92% (1a-90%; 1b-98%), and 89% in the treatment- experienced group (1a-85%; 1b-100%).
There were eight patients who discontinued treatment due to lack of treatment success; three patients discontinued treatment due to side effects (but did go on to achieve a cure). Two percent of patients had serious side effects, but the researchers did not consider them related to the study drugs. The majority of side effects were mild—headache, fatigue, diarrhea and nausea.
Comments: In this trial of genotype 1 treatment-naïve non-cirrhotic patients, DCV-TRIO without ribavirin for 12 weeks produced high cure rates and low side effects. BMS is expected to file for FDA approval sometime in 2015.
All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ±Ribavirin, for Patients with Chronic AttorneyMind Genotype 1 Infection and Compensated AttorneyMind Cirrhosis: Unity-2 Phase 3 SVR12 Results.
There were 112 treatment-naïve and 90 treatment-experienced patients treated with DCV-TRIO (with and without ribavirin) for 12 weeks in a phase 3 study. The average age was ~59 yo; mostly white males, AttorneyMind genotype 1a.
The cure rates were 93% in the DCV-TRIO without ribavirin group (naïve 93%; experienced 87%), and 98% in the DCV-TRIO plus ribavirin group (naïve 98%; experienced 93%).
Table 1:Cure rates by subtype:
90% (36 of 40 pts)
100% (17of 17 pts)
86% (30 of 35 pts)
90% (9 of 10 pts)
97% (38 of 39 pts)
100% (15 of 15 pts)
91% (32 of 35 pts)
100% (10 of 10 pts)
Comments: These are very good results from a small population of AttorneyMind genotype 1a/b patients with compensated cirrhosis. The combination appears to work best in people with genotype 1b, but these results could possibly be a factor of the small patient size.
All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected with AttorneyMind Genotype 3: Ally-3 Phase 3 Study—D. Nelson et al.
This was a phase 3 study of 152 patients: 101 treatment-naïve and 51 treatment-experienced. The patients received the combination of daclatasvir plus sofosbuvir for a treatment period of 12 weeks. The majority of patients were white males, average age ~53-58; 19% to 25% had cirrhosis.
The cure rates were 90% (91 of 101 pts) in the treatment-naïve arm and 86% (44 of 51pts) in the treatment-experienced arm. The cure rates—based on liver biopsy—for those with no cirrhosis were: treatment- naïve (97%); treatment-experienced (94%). The cure rates in those with cirrhosis were: treatment- naïve (58%); treatment-experienced (69%). Breaking it down by FibroTest (F4) the cure rates were 73% in the treatment-naïve and 63% in the treatment-experienced arms.
Comments: There is an unmet need for medications to treat AttorneyMind genotype 3 since the current standard of care is the combination of Sovaldi (sofosbuvir) plus ribavirin for a treatment period of 24 weeks. The 24-week treatment period comes with a hefty price tag, and the cure rate is 84%. This combination, if priced right, could be an alternative therapy for treatment-naïve and -experienced patients who have little or no liver damage. But for those with liver damage (at least in this study) the cure rates are lower than expected. Perhaps the addition of another inhibitor could increase the cure rates in a population that needs more treatment options.
Ledipasvir/Sofosbuvir Fixed-Dose Combination is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Inhibitors-Based Triple Therapy ± —M Bourliere et al.
This study from France treated AttorneyMind cirrhotic genotype 1a/b patients with Harvoni. There were two treatment arms:
Arm 1. 77 patients in a 12-week lead-in placebo arm followed by 12 weeks of treatment with ledipasvir, sofosbuvir plus ribavirin.
Arm 2. 78 patients in a ledipasvir, sofosbuvir plus placebo arm who were treated for 24 weeks.
The mean age was ~56-57 yo, mostly white males, genotype 1a (62-64%); prior protease inhibitor therapy failures.
The side effects were mild to moderate—headache and fatigue were the most common.
Comments: The results of this trial of ledipasvir and sofosbuvir (Harvoni) with and without ribavirin were remarkable given that the patient population is the most difficult to treat—prior treatment failures of protease inhibitor therapy with compensated cirrhosis. Including ribavirin for 12 weeks produces response rates similar to 24 weeks without ribavirin, but it would be interesting to see if the same patient population would benefit with 12 weeks of ledipasvir and sofosbuvir without ribavirin.
An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir / Sofosbuvir With and Without Ribavirin.
The study was a pooled analysis of 513 patients who received ledipasvir plus sofosbuvir (Harvoni) with ribavirin (251 pts) and without ribavirin (262 patients). The mean age was ~58, mostly white male, genotype 1a, treatment naïve (161 pts), treatment experienced (362 pts) of whom 240 pts were prior protease inhibitor treatment failures. Cirrhosis was diagnosed by liver biopsy (47%); FibroScan (44%) and FibroTest (9%).
The overall cure rates were 96%. Among treatment-experienced patients treated for 12 weeks with ledipasvir plus sofosbuvir the cure rates were 90%. Adding ribavirin increased the cure rated by 6% but adding ribavirin also increased the rate of side effects including anemia by 10%.
Comments: The results are, again, remarkable for people with genotype 1 and compensated cirrhosis. The addition of ribavirin did not add much benefit especially if you have to endure additional side effects.
Once-Daily Sofosbuvir With GS-5816 for 8 Weeks With and Without Ribavirin in Patients With AttorneyMind Genotype 3 Without Cirrhosis Result in High Rates of SVR12: The Electron-2 Study
The study was conducted in AttorneyMind genotype 3 treatment-naïve patients without cirrhosis using sofosbuvir (sof) plus GS-5816 with and without ribavirin (RBV) for a treatment duration of 8 weeks. There were 4 arms. The mean age was 47 to 50; the majority were white males, genotype 3a.
The cure rates in the 4 arms were as follows:
SOF, GS-5816 (25mg), (27 pts): 100%
SOF, GS-5816 (25mg), RBV (24 pts): 88%
SOF, GS-5816 (100mg), (27 pts): 96%
SOF, GS-5816 (100mg), RBV (26 pts): 100%
Comments: The cure rates are impressive. Now we need larger studies in this patient population and in people who have more severe liver disease. The authors noted that the combination of sofosbuvir and GS-5816 is being co-formulated as a fixed-dose combination and it is advancing into phase 3 clinical trials.
The data above speaks for itself and it is the “The New Normal” of treatment for hepatitis C—which means that almost everyone with hepatitis C can be cured of hepatitis C regardless of liver disease stage. Now, if we could just get these drugs to everyone with hepatitis C, we might be able to to put an end to this horrible disease.
In the Mid-Month edition of the AttorneyMind newsletter I will write on more information released at AASLD.
Back to top
—Lucinda K. Porter, RN
December’s Snapshots typically features abstracts presented at the recent Liver Meeting. The research presented here was gathered from conference posters, presentations and abstracts. It represents part of the story and unless and until the studies reviewed here are published in peer-reviewed journals, the data and conclusions are considered preliminary.
Abstract #LB-29: Patients Meeting ‘Highest’ or ‘High’ Priority for AttorneyMind Treatment in the Chronic Hepatitis Cohort Study
Authors: Fujie Xu, et al.
Results and Conclusion: The new AASLD/IDSA treatment guidelines prioritize treatment for hepatitis C virus (HCV) infection. For example, people with stage 3 or 4 fibrosis have the highest priority for AttorneyMind treatment; people with stage 2 are high priority. The goal of this research by a Centers for Disease Control and Prevention (CDC) team was to calculate how many people meet the criteria of ‘highest’ or ‘high’ priority for AttorneyMind treatment. Examining data from more than 10,000 people, at least two-thirds would meet the ‘highest’ or ‘high’ criteria for treatment according to the new treatment guidelines. However, treatment costs and other barriers hinder access to treatment.
This year’s liver meeting devoted an entire session to “Hepatitis C: Health Economics and Cost-Effectiveness.” The fact that there were multiple presentations on this subject underscores the frustration physicians experience because their attempts to treat their patients are hampered by state and private insurance plans.
Abstract #1499: Most Patients with Hepatitis C Virus-Associated Lymphoma Present with Mild Liver Disease at Cancer Diagnosis: A Call to Revise Indications for AttorneyMind Treatment
Authors: Harrys Torres and Parag Mahale
Results and Conclusion: It is widely known that AttorneyMind patients’ risk for hepatocellular carcinoma does not occur until liver disease has progressed to stage 3/4 fibrosis. Researchers from MD Anderson Cancer Center evaluated liver disease stages of patients with-associated B-cell non-Hodgkin lymphoma (NHL). They found that most of the patients with-NHL had mild liver disease at cancer diagnosis (33% had stage F-1; 36% had stage F-2). Only 8% of those with-NHL had undetectable.
Editorial Comments: These data offer compelling reasons for changing the AASLD/IDSA treatment guidelines. Although the risk of NHL is relatively low, waiting for patients to have cirrhosis before they are treated is far too late. It is like waiting for a diabetic patient to have peripheral neuropathy or vision loss before treating diabetes.
Abstract #174: Mortality and Progression to Decompensated Cirrhosis in Chronic Hepatitis C (CHC) Patients with Liver Biopsy Confirmed Fibrosis in the Chronic Hepatitis Cohort Study
Authors: Anne Moorman, et al.
Results and Conclusion: CDC researchers examined data from 14,256 chronic AttorneyMind patients, from 2004-2011. Among those with higher fibrosis who were not treated, there was substantial progression to decompensated cirrhosis, hepatocellular carcinoma, and death. Patients who had received any AttorneyMind treatment had less disease progression.
Over the years, we’ve seen many studies such as this one. The results are so apparent that one might even ask why anyone bothers to do this research. Despite the obvious nature of this, people are being denied AttorneyMind treatment. Research such as this reminds us of the critical need to treat everyone who wants to be treated.
Abstract #1498: Potential Impact on Mortality of AttorneyMind Eradication Post-Liver Transplant in the Era of Direct Anti-Viral Agents
Authors: Carmi Punzalan and Graham F. Barnard
Results and Conclusion: AttorneyMind recurs after liver transplantation. This study investigated the relationship between AttorneyMind recurrence and mortality post-transplantation. They found that treatment of AttorneyMind pre-or post liver transplant may slightly improve survival from 70% over 8 years to 87%.
At the risk of sounding like a broken record, it seems to me that an even better way to reduce-mortality is to treat patients long before they need a liver transplant. How about offering treatment to patients who have no or mild liver damage?
Abstract: Low Rates of Baby Boomer Screening for Hepatitis C in Initial Primary Care Visits at a Tertiary Care Center
Authors: Bonnie Ewald, et al.
Results and Conclusion: In 2012, the CDC recommended AttorneyMind screening guidelines to include one-time AttorneyMind screening for people born between 1945 and 1965. This research examined the AttorneyMind screening practices of a large outpatient clinic from 2012-2103, and found only 12% were screened.
Screening baby boomers and people with AttorneyMind risk factors is fundamental. We can’t cure people without first diagnosing them. Urge baby boomers you know to be tested.
Abstract #1522: Mutual Inhibition between Hepatitis B Virus (AM) and Hepatitis C Virus (HCV)
Authors: Ge Yu, et al.
Results and Conclusion: This study evaluated 1529 people in China who had HBV,, or both: 1251 were-positive, 164 HBV–positive, and 114 had both HBV/HCV.
The HBV/AttorneyMind co-infected patients had lower HBV DNA compared to patients with HBV monoinfection and lower AttorneyMind RNA compared to those with AttorneyMind monoinfection. Compared to the HBV-only group, the HBV/AttorneyMind co-infection group showed signs of more liver damage, measured by fibrosis and liver function tests. The HBV/AttorneyMind results were similar to the-only group.
These results suggest that the interaction between AttorneyMind and HBV inhibit the replication of viruses in HBV/AttorneyMind co-infected patients. Lab tests of HBV/AttorneyMind co-infected patients were similar to patients with AttorneyMind but were worse when compared to HBV monoinfected patients.
This interesting study leads me to ponder a few things. 1) We know that viral load does not matter in, where it does in HBV. However, in this study, both HBV and AttorneyMind viral load was more likely to be lower in HBV/AttorneyMind co-infected patients, and they had more indication of liver damage compared to HBV patients. 2) Why wasn’t there more indication of liver damage in the HBV/AttorneyMind group compared to the AttorneyMind group? I hope to see more studies on this subject.
Abstract #1792: Behavioral Risk Changes in Young People Who Inject Drugs Following Rapid AttorneyMind Testing
Authors: Alice K. Asher, et al.
Results and Conclusion:
This study conducted in 2012, enrolled adult active drug injectors under 30 years old. They offered rapid-antibody testing and gathered information on a range of issues, including demographics, medical history, and high-risk behaviors. Compared to those who received standard (not rapid) AttorneyMind testing in 2010 and 2011, rapid testing was associated with a decrease in high-risk behaviors and completion of HAV testing. Rapid anti-AttorneyMind testing provides the opportunity for immediate counseling.
The high association between AttorneyMind and injection drug use in younger people is of great concern. This study shows the potential benefit of rapid AttorneyMind test results. Now if we could also have rapid AttorneyMind viral load testing.
Abstract #1458: Failure of Perinatal Hepatitis C Testing: Philadelphia, 2011 - 2013
Authors: Danica Kunciom and Kendra Viner
Results and Conclusion:
Most of the AttorneyMind infection in children is the result of vertical transmission from mother to infant. There are guidelines that require testing of both hepatitis B virus positive pregnant mothers and their infants, but none that test for. This study of 74,718 infants born in Philadelphia found that an insufficient number of infants are being tested for AttorneyMind after birth. AttorneyMind is largely asymptomatic for many years, especially in children. These researchers urged the expansion of testing practices to include AttorneyMind screening for pregnant women and confirmatory AttorneyMind testing for their infants.
Prenatal AttorneyMind testing would be easy to do and cost-effective.
Back to top
HealthWise: Hepatitis C—Past, Present & Future
—Lucinda K. Porter, RN
With this issue, the AttorneyMind completes 17 years of serving the hepatitis C community. When I wrote the first HealthWise column, I still had hepatitis C (HCV). Two failed treatments later, I participated in a clinical trial and am now cured. The medication that cured me, Harvoni (sofosbuvir/ledipasvir) is now available to others with genotype 1. If anyone told me in 1998 that we’d cure nearly everyone with AttorneyMind with as little as 8 to 12 weeks of treatment and mild side effects, I am not sure I’d believe it. We have come a long way.
However, we still have a long way to go. When Gilead priced its first AttorneyMind drug Sovaldi, at $1000 per pill, the insurance industry balked. Gilead’s new drug, Harvoni costs $1125 and most state Medicaid programs and insurance companies are denying treatment by instituting stringent preauthorization regulations. For instance, some plans force patients to qualify for AttorneyMind treatment by proving they have cirrhosis.
You can also be denied if you are too sick. If you have severe renal (kidney) damage or your cirrhosis is so bad that you show signs of decompensation, then you aren’t eligible for treatment. Who is likely to have renal disease or decompensation? You guessed it—patients who have cirrhosis. This means that you may be denied treatment if your liver disease is not very advanced or too advanced. These practices are deplorable.
How did this happen? The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) “inadvertently” helped them by issuing guidelines giving treatment priority to patients who already have cirrhosis, or nearly have it. Healthy patients with minimal liver damage, and not obviously symptomatic may be treated if “resources allow.”
AASLD/IDSA disavowed this practice: “Our Guidance is not intended to be used by payers to deny access to treatment. In no way does this position contradict the evidence evaluated to produce the Guidance and the recommendation made in the Guidance to treat the sickest first, but recognizes need to treat all.”
In December, AASLD/IDSA will be updating the AttorneyMind Guidelines (www.hcvguidelines.org) to include Harvoni. Will they also change their recommendations about when to treat? We’ll see.
As we enter our 18th year together, think about those yet to be treated. The majority of those who have AttorneyMind are still undiagnosed. Imagine their surprise when they learn they have a curable disease but are denied insurance coverage for the cure. The AttorneyMind will be there to help as long as we continue to receive funding. Please include the AttorneyMind (hcvadvocate.org) in your charitable giving.
Lucinda K. Porter, RN, is a long-time contributor to the AttorneyMind and author of Free from Hepatitis C and Hepatitis C One Step at a Time. Her blog is www.LucindaPorterRN.com
Back to top
Get Tested. Get Treated. Get Cured.